DL-PPMP CAS: 149022-18-4
MF: C29H50N2O3•HCl
MW: 511.18
An inhibitor of glucosylceramide synthetase.

DL-PPMP (CAS 149022-18-4)

DL-PPMP | CAS 149022-18-4 is rated 5.0 out of 5 by 1.
  • y_2020, m_8, d_9, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205655, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 130ms
  • REVIEWS, PRODUCT
5
1
4
0
3
0
2
0
1
0
Alternate Names: DL-threo-1-Phenyl-2-palmitoylamino-3-morpholino-1-propanol hydrochloride
Application: DL-PPMP is an inhibitor of glucosylceramide synthetase
CAS Number: 149022-18-4
Purity: ≥98%
Molecular Weight: 511.18
Molecular Formula: C29H50N2O3•HCl
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

DL-PPMP inhibits UGCG (glucosylceramide synthase) and is more effective than PDMP in intact cells.


References

1. Abe, A., et al. 1992. J. Biochem. 111: 191-196. PMID: 1533217

Physical State :
Solid
Solubility :
Soluble in DMSO, ethanol, and water.
Storage :
Store at -20° C
Refractive Index :
n20D 1.51
pK Values :
pKa: 13.60, pKb: 6.50
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
49837889
MDL Number :
MFCD00211157
SMILES :
CCCCCCCCCCCCCCCC(=O)N[[email protected]](CN1CCOCC1)[[email protected]@H](C2=CC=CC=C2)O.Cl

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

DL-PPMP (CAS 149022-18-4)  Product Citations

See how others have used DL-PPMP (CAS 149022-18-4). Click on the entry to view the PubMed entry .

Citations 1 to 1 of 1 total

PMID: # 26678556  Mikami, J.|Tobisawa, Y.|Yoneyama, T.|Hatakeyama, S.|Mori, K.|Hashimoto, Y.|Koie, T.|Ohyama, C.|Fukuda, M.| et al. 2016. Cancer Sci. 107: 359-68.

Citations 1 to 1 of 1 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 130ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from Yang Yang, Q. et al. (PubMed 15257901) found that inhibition of glucosylceramide synthase (GCS) and mdr1 gene expressions is positively correlated with the concentrations of DL-PPMP and verapamil, which can reverse multidrug resistance (MDR) by inhibiting synthesis of GCS and mdr1 gene, indicating the positive correlation between the expression of GCS gene and MDR in KBV(200) cells. -SCBT Publication Review
Date published: 2015-03-29
  • y_2020, m_8, d_9, h_16
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.10
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_205655, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 21ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.